Hypothesis: Redundancy Engineering — A Testable Protocol for Systems-Level Longevity

The longevity field is converging on a critical insight: robustness through redundancy beats optimization of single targets. But "network topology" remains frustratingly abstract. Here's how we make it concrete.

Core claim: We can engineer redundancy into biological systems by creating parallel, semi-independent pathways for critical functions — and test this via sequential pathway inhibition experiments.

Why this matters: 15-PGDH and other "gerozymes" show druggable single targets work, but species-level longevity differences arise from systems architecture, not individual pathways. We need a bridge from theory to testable intervention.